This study assessed the pharmacokinetics, safety and efficacy of intravenous enoxaparin in
patients undergoing percutaneous coronary intervention (PCI). Sixty consecutive patients …

The objective of this study was to evaluate the pharmacokinetic response to intravenous (IV)
enoxaparin given 8–12 hr after subcutaneous (SC) dosing in patients undergoing …

This pilot study was designed to determine whether the low molecular weight heparin,
enoxaparin, could be used for elective percutaneous coronary intervention (PCI) to provide …

Objectives: This study was designed to examine a unique and low dose of intravenous
enoxaparin in elective percutaneous coronary intervention (PCI) that would be applicable to …

Plasma anti‐Xa activity after Enoxaparin administration in patients with acute coronary
syndrome (ACS) undergoing coronary angiography and percutaneous coronary intervention …

Background: Many cardiologists continue to be reluctant to utilize low-molecular-weight
heparin in the treatment of patients with non-ST-segment-elevation acute coronary …

Increasing evidence suggests that treatment with the low molecular weight heparin
enoxaparin during percutaneous coronary intervention (PCI) is safe and effective. We …

We sought to determine the safety and efficacy of enoxaparin versus unfractionated heparin
during percutaneous coronary intervention (PCI). Four hundred ninety-three consecutive …

Unfractionated heparin (UFH) has been the standard choice of adjunctive antithrombotic
therapy during elective percutaneous coronary intervention (PCI). Evidence is emerging that …

Randomized controlled trials of patients with non-ST segment elevation acute coronary
syndromes have established the superiority of enoxaparin (versus unfractionated heparin) …